4.8 Article

TAp63-Regulated miRNAs Suppress Cutaneous Squamous Cell Carcinoma through Inhibition of a Network of Cell-Cycle Genes

Journal

CANCER RESEARCH
Volume 80, Issue 12, Pages 2484-2497

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-19-1892

Keywords

-

Categories

Funding

  1. Moffitt Cancer Center Support Grant [P30CA076292]
  2. Cancer Prevention Institute of Texas (CPRIT) [RP170005]
  3. NIH P30 shared resource grant [CA125123]
  4. NIEHS P30 Center grant [1P30ES030285]
  5. Proteomics Core at Moffitt Cancer Center, an NCI-designated Comprehensive Cancer Center [P30-CA076292]
  6. Flow Cytometry Core Facility at Moffitt Cancer Center, an NCI-designated Comprehensive Cancer Center [P30-CA076292]
  7. Small Animal Imaging Laboratory at Moffitt Cancer Center, an NCI-designated Comprehensive Cancer Center [P30-CA076292]
  8. Tissue Histology Core at Moffitt Cancer Center, an NCI-designated Comprehensive Cancer Center [P30-CA076292]
  9. [R35CA197452]

Ask authors/readers for more resources

TAp63 is a p53 family member and potent tumor and metastasis suppressor. Here, we show that TAp63(-/-) mice exhibit an increased susceptibility to ultraviolet radiation-induced cutaneous squamous cell carcinoma (cuSCC). A human-to-mouse comparison of cuSCC tumors identified miR-30c-2* and miR-497 as underexpressed in TAp63-deficient cuSCC. Reintroduction of these miRNAs significantly inhibited the growth of cuSCC cell lines and tumors. Proteomic profiling of cells expressing either miRNA showed downregulation of cell-cycle progression and mitosis-associated proteins. A mouse to human and cross-platform comparison of RNA-sequencing and proteomics data identified a 7-gene signature, including AURKA, KIF18B, PKMYT1, and ORC1, which were overexpressed in cuSCC. Knockdown of these factors in cuSCC cell lines suppressed tumor cell proliferation and induced apoptosis. In addition, selective inhibition of AURKA suppressed cuSCC cell proliferation, induced apoptosis, and showed antitumor effects in vivo. Finally, treatment with miR-30c-2* or miR-497 miRNA mimics was highly effective in suppressing cuSCC growth in vivo. Our data establish TAp63 as an essential regulator of novel miRNAs that can be therapeutically targeted for potent suppression of cuSCC. Significance: This study provides preclinical evidence for the use of miR-30c-2*/miR-497 delivery and AURKA inhibition in the treatment of cuSCC, which currently has no FDA-approved targeted therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available